Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: International Journal of Molecular Sciences. 22
- Event
-
Veröffentlichung
- (where)
-
Leipzig
- (who)
-
Universitätsbibliothek Leipzig
- (when)
-
2024
- Creator
-
Goehringer, Nils
Biersack, Bernhard
Peng, Yayi
Schobert, Rainer
Herling, Marco
Ma, Andi
Nitzsche, Bianca
Höpfner, Michael
- URN
-
urn:nbn:de:bsz:15-qucosa2-892218
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:41 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Goehringer, Nils
- Biersack, Bernhard
- Peng, Yayi
- Schobert, Rainer
- Herling, Marco
- Ma, Andi
- Nitzsche, Bianca
- Höpfner, Michael
- Universitätsbibliothek Leipzig
Time of origin
- 2024
Other Objects (12)
New chimeric HDAC inhibitors for the treatment of colorectal cancer
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Development of dual BET/HDAC inhibitors
Design and synthesis of novel quinazoline-based EGFR kinase inhibitors and dual EGFR/NF-κB inhibitors as potential anti-cancer drugs with enhanced efficacy
Optimization of chimeric antigen receptor (CAR) therapy
The Role of EGFR
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Chimeric toxins for specific targeting of cancer cells
Total synthesis of natural HDAC inhibitors and derivatives thereof
Engineering of chimeric polyketide synthases using SYNZIP docking domains
Development of novel parvovirus-based anticancer therapies
New chimeric HDAC inhibitors for the treatment of colorectal cancer
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Development of dual BET/HDAC inhibitors
Design and synthesis of novel quinazoline-based EGFR kinase inhibitors and dual EGFR/NF-κB inhibitors as potential anti-cancer drugs with enhanced efficacy
Optimization of chimeric antigen receptor (CAR) therapy
The Role of EGFR
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Chimeric toxins for specific targeting of cancer cells
Total synthesis of natural HDAC inhibitors and derivatives thereof
Engineering of chimeric polyketide synthases using SYNZIP docking domains
Development of novel parvovirus-based anticancer therapies
New chimeric HDAC inhibitors for the treatment of colorectal cancer
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Development of dual BET/HDAC inhibitors
Design and synthesis of novel quinazoline-based EGFR kinase inhibitors and dual EGFR/NF-κB inhibitors as potential anti-cancer drugs with enhanced efficacy
Optimization of chimeric antigen receptor (CAR) therapy
The Role of EGFR
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Chimeric toxins for specific targeting of cancer cells
Total synthesis of natural HDAC inhibitors and derivatives thereof
Engineering of chimeric polyketide synthases using SYNZIP docking domains